Merck SILuProt IGFBP7 Insulin-like growth factor-binding protein 7 human

SILu™Prot IGFBP7 Insulin-like growth factor-binding protein 7 human

recombinant, expressed in HEK 293 cells, SIL MS Protein Standard, 13C and 15N-labeled

IGF-bindingprotein7, IGFBP-7, PGI2-stimulating factor, Tumor-derived adhesion factor (TAF), IBP-7, IGFBP-rP1, MAC25 protein, Prostacyclin-stimulating factor, IGF-binding protein 7

Quality Level

200

생물학적 소스

human

재조합

expressed in HEK 293 cells

assay

≥98% (SDS-PAGE)

form

lyophilized powder

효능

≥98 Heavy amino acids incorporation efficiency by MS

technique(s)

mass spectrometry (MS): suitable

적합성

suitable for mass spectrometry (standard)

UniProt 수납 번호

Q16270

저장 온도

−20°C

Gene Information

human ... IGFBP7(3490)

IGFBP7 regulates the availability of insulin-like growth factors (IGFs) in tissue, and modulates IGF binding to its receptors. IGFBP7 binds to IGF with high affinity. Several studies have shown the involvement of IGFBP7 in Acute Kidney Injury (AKI), where its levels can predict patients at risk for developing AKI. When combined with TIMP-2, the accuracy of AKI risk prediction is further increased. Urinary [TIMP-2]×[IGFBP7] test sufficiently detects patients with risk of AKI after major non-cardiac surgery. In addition, Urinary [TIMP-2]×[IGFBP7] serves as a sensitive and specific biomarker to predict AKI early after cardiac surgery and to predict renal recovery.